HERON THERAPEUTICS, INC. /DE/ - Common Stock (HRTX)

Q1 2023 13F Holders as of 31 Mar 2023

Type / Class
Equity / Common Stock
Shares outstanding
183,558,579
Total 13F shares
107,852,430
Share change
-7,897,150
Total reported value
$162,855,915
Put/Call ratio
249%
Price per share
$1.51
Number of holders
153
Value change
-$15,688,602
Number of buys
57
Number of sells
81

Institutional Holders of HERON THERAPEUTICS, INC. /DE/ - Common Stock (HRTX) as of Q1 2023

As of 31 Mar 2023, HERON THERAPEUTICS, INC. /DE/ - Common Stock (HRTX) was held by 153 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 107,852,430 shares. The largest 10 holders included FRANKLIN RESOURCES INC, Rubric Capital Management LP, BlackRock Inc., VANGUARD GROUP INC, BAKER BROS. ADVISORS LP, JPMORGAN CHASE & CO, GREAT POINT PARTNERS LLC, Velan Capital Investment Management LP, PALISADE CAPITAL MANAGEMENT, LP, and ArrowMark Colorado Holdings LLC. This page lists 153 institutional shareholders reporting positions in this security for the Q1 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.